Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1827101rdf:typepubmed:Citationlld:pubmed
pubmed-article:1827101lifeskim:mentionsumls-concept:C0332307lld:lifeskim
pubmed-article:1827101lifeskim:mentionsumls-concept:C0085504lld:lifeskim
pubmed-article:1827101lifeskim:mentionsumls-concept:C0080194lld:lifeskim
pubmed-article:1827101lifeskim:mentionsumls-concept:C0055856lld:lifeskim
pubmed-article:1827101lifeskim:mentionsumls-concept:C0282563lld:lifeskim
pubmed-article:1827101lifeskim:mentionsumls-concept:C0441655lld:lifeskim
pubmed-article:1827101pubmed:dateCreated1991-6-4lld:pubmed
pubmed-article:1827101pubmed:abstractTextThe activity of oxytetracycline and seven macrolide antibiotics was investigated against a prototype strain of Chlamydia pneumoniae in cell culture. Following incubation, inoculated cell monolayers were fixed in methanol and stained with a genus specific immunofluorescent monoclonal antibody before examination for inhibition of inclusion formation. The most active agent was clarithromycin (MIC 0.007 mg/l), followed by erythromycin (0.06 mg/l). Other macrolides were less active; josamycin and roxithromycin (0.25 mg/l), midecamycin acetate and azithromycin (0.5 mg/l) and spiramycin (4.0 mg/l). The MIC of oxytetracycline was 0.25 mg/l. Clinical evaluation of clarithromycin for C. pneumoniae lower respiratory infection is indicated.lld:pubmed
pubmed-article:1827101pubmed:languageenglld:pubmed
pubmed-article:1827101pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1827101pubmed:citationSubsetIMlld:pubmed
pubmed-article:1827101pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1827101pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1827101pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1827101pubmed:statusMEDLINElld:pubmed
pubmed-article:1827101pubmed:monthFeblld:pubmed
pubmed-article:1827101pubmed:issn0305-7453lld:pubmed
pubmed-article:1827101pubmed:authorpubmed-author:RidgwayG LGLlld:pubmed
pubmed-article:1827101pubmed:authorpubmed-author:MumtazGGlld:pubmed
pubmed-article:1827101pubmed:authorpubmed-author:FenelonLLlld:pubmed
pubmed-article:1827101pubmed:issnTypePrintlld:pubmed
pubmed-article:1827101pubmed:volume27 Suppl Alld:pubmed
pubmed-article:1827101pubmed:ownerNLMlld:pubmed
pubmed-article:1827101pubmed:authorsCompleteYlld:pubmed
pubmed-article:1827101pubmed:pagination43-5lld:pubmed
pubmed-article:1827101pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1827101pubmed:meshHeadingpubmed-meshheading:1827101-...lld:pubmed
pubmed-article:1827101pubmed:meshHeadingpubmed-meshheading:1827101-...lld:pubmed
pubmed-article:1827101pubmed:meshHeadingpubmed-meshheading:1827101-...lld:pubmed
pubmed-article:1827101pubmed:meshHeadingpubmed-meshheading:1827101-...lld:pubmed
pubmed-article:1827101pubmed:meshHeadingpubmed-meshheading:1827101-...lld:pubmed
pubmed-article:1827101pubmed:meshHeadingpubmed-meshheading:1827101-...lld:pubmed
pubmed-article:1827101pubmed:year1991lld:pubmed
pubmed-article:1827101pubmed:articleTitleThe in-vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae (TWAR).lld:pubmed
pubmed-article:1827101pubmed:affiliationDepartment of Clinical Microbiology, University College Hospital, London, UK.lld:pubmed
pubmed-article:1827101pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1827101pubmed:publicationTypeComparative Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1827101lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1827101lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1827101lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1827101lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1827101lld:pubmed